INT158015

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 2009
Last Reported 2010
Negated 5
Speculated 1
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 1.66
Pain Relevance 0.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (FLT1) endosome (FLT1) Golgi apparatus (FLT1)
cytoplasm (FLT1) extracellular space (FLT1) extracellular region (FLT1)
Anatomy Link Frequency
plasma 10
muscle tissues 2
FLT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 1 89.28 High High
Clonidine 2 65.12 Quite High
metalloproteinase 24 49.76 Quite Low
addiction 24 5.00 Very Low Very Low Very Low
antagonist 24 5.00 Very Low Very Low Very Low
ischemia 16 5.00 Very Low Very Low Very Low
Inflammation 10 5.00 Very Low Very Low Very Low
Restless leg syndrome 8 5.00 Very Low Very Low Very Low
Central nervous system 8 5.00 Very Low Very Low Very Low
cytokine 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Eclampsia 34 99.30 Very High Very High Very High
Adult Respiratory Distress Syndrome 28 97.92 Very High Very High Very High
Hypoxia 10 94.08 High High
Nicotine Addiction 1 93.04 High High
Pulmonary Fibrosis 1 90.96 High High
Lung Injury 4 76.72 Quite High
Fibromyalgia 12 75.00 Quite High
Hypertension 10 75.00 Quite High
Peripheral Arterial Disease 144 53.52 Quite High
Cancer 40 48.08 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
With the exception of frusemide, none of the antihypertensive drugs tested had any effect on sFlt-1 and sEng production from placental explants of normal pregnancy and women with pre-eclampsia.
Regulation (effect) of Gene_expression (production) of sFlt-1 associated with eclampsia
1) Confidence 0.52 Published 2009 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 19215236 Disease Relevance 0.41 Pain Relevance 0.07
The clinical implication is that pathological levels of plasma sVEGFR1 may not necessarily indicate altered sVEGFR1 production or altered availability of free VEGF, because they may partially reflect altered receptor expression in tissues.
Regulation (altered) of Gene_expression (production) of sVEGFR1 in plasma
2) Confidence 0.51 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
In conclusion, placental sFlt-1 and sEng production was higher in pre-eclampsia and antihypertensive drugs had no effect on placental production of sFlt-1 and sEng in vitro.
Neg (no) Regulation (effect) of Gene_expression (production) of sFlt-1 associated with eclampsia
3) Confidence 0.38 Published 2009 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 19215236 Disease Relevance 0.48 Pain Relevance 0.05
Transport parameters affected concentrations of plasma VEGF, plasma sVEGFR1 and interstitial sVEGFR1, but not surface-bound VEGFR occupancy
Neg (not) Regulation (affected) of Gene_expression (concentrations) of sVEGFR1 in plasma
4) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Receptor heterodimers were neglected in this model for the lack of in vivo quantification of their relative abundance, and would not have affected current predictions of sVEGFR1's effects on the VEGF system until the focus of study switches to sVEGFR1's alternate role in heterodimerizing with surface VEGFRs.
Neg (not) Regulation (affected) of Gene_expression (effects) of sVEGFR1
5) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Introduction of homodimerized sVEGFR1 and lymphatic drainage did not drastically alter VEGF ligand and receptor distributions in healthy muscle tissues
Neg (not) Regulation (alter) of Gene_expression (Introduction) of sVEGFR1 in muscle tissues
6) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.05 Pain Relevance 0
As a first assessment of whether activity-dependent kL can account for the surge in plasma sVEGFR1 observed after acute exercise in healthy individuals, simulations were performed without concurrent exercise-induced changes to sVEGFR1 or VEGF production, kP, or receptor expression.
Regulation (changes) of Gene_expression (production) of sVEGFR1 in plasma
7) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Transport parameters affected concentrations of plasma VEGF, plasma sVEGFR1 and interstitial sVEGFR1, but not surface-bound VEGFR occupancy
Neg (not) Regulation (affected) of Gene_expression (concentrations) of sVEGFR1 in plasma
8) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Changing levels of circulating sVEGFR1 may reflect altered tissue expression of surface receptors
Spec (may) Regulation (reflect) of Gene_expression (levels) of sVEGFR1
9) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
The significance here is that the physiological variation in transport rates offers a case example where the common circulating angiogenic markers become unreliable, i.e., apparent changes in free VEGF or sVEGFR1 levels in the plasma do not correlate with changes in the actual angiogenic signaling potential in the tissues.
Regulation (changes) of Gene_expression (levels) of sVEGFR1 in plasma
10) Confidence 0.22 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Increased levels of soluble VEGFR-1(s-flt) have been demonstrated to contribute to these observations (23).
Regulation (contribute) of Gene_expression (levels) of VEGFR-1
11) Confidence 0.10 Published 2010 Journal American Journal of Physiology - Lung Cellular and Molecular Physiology Section Body Doc Link PMC2886605 Disease Relevance 0.72 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox